BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
576 results:

  • 1. Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer.
    Rodriguez GF; Shah A; Maderal AD
    Breast Dis; 2024; 43(1):61-64. PubMed ID: 38578876
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
    Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Synergistic antitumor activity between her2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal her2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
    Connolly RM; Wang V; Hyman DM; Grivas P; Mitchell EP; Wright JJ; Sharon E; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Wang J; Wisinski KB; Tricoli JV; Conley BA; Harris LN; Arteaga CL; O'Dwyer PJ; Chen AP; Flaherty KT
    Clin Cancer Res; 2024 Apr; 30(7):1273-1280. PubMed ID: 38433347
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for her2-positive tumors.
    Zhao S; Qiu Y; Yuan M; Wang Z
    Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [A Case of Advanced Recurrent Rectal cancer Successfully Treated by Rechallenge Therapy with an Anti-Epidermal Growth Factor Receptor(EGFR)Drug].
    Sakuma T; Shibutani M; Fukuoka T; Kasashima H; Nishiyama M; Fukui Y; Natsuki S; Nishiyama T; Maruo K; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1504-1506. PubMed ID: 38303322
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212).
    Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
    Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance.
    Kusumaningrum AE; Makaba S; Ali E; Singh M; Fenjan MN; Rasulova I; Misra N; Al-Musawi SG; Alsalamy A
    Cell Biochem Funct; 2024 Jan; 42(1):e3906. PubMed ID: 38269502
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Novel immunotherapies for breast cancer: Focus on 2023 findings.
    Lan HR; Chen M; Yao SY; Chen JX; Jin KT
    Int Immunopharmacol; 2024 Feb; 128():111549. PubMed ID: 38266449
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
    Bando H; Yamaguchi K; Mitani S; Sawada K; Mishima S; Komine K; Okugawa Y; Hosoda W; Ebi H
    Cancer Sci; 2024 Mar; 115(3):1014-1021. PubMed ID: 38263580
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Updates on immunotherapy of gastrointestinal cancers and practical challenges].
    Chen F; Wang F; Xu RH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jan; 27(1):24-34. PubMed ID: 38262897
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Impact of tissue-agnostic approvals on management of primary brain tumors.
    Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
    Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
    Roskoski R
    Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Efficacy of Pyrotinib With/Without Trastuzumab in treatment-Refractory, her2-Positive Metastatic colorectal cancer: Result From a Prospective Observational Study.
    Zhou H; Lv M; Li W; Wang Y; Wu J; Liu Q; Liu T; Cui Y; Li Q
    Clin Colorectal Cancer; 2024 Mar; 23(1):58-66. PubMed ID: 38177002
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Learning Outcomes of "GetSMART," Education for Diagnostics and Targeted treatment for her2+ Metastatic Gastric and colorectal cancers.
    Augustyniak M; Lou E; Jacobs G; Fleming M; Marshall J; Coutinho A; Yoshino T
    J Cancer Educ; 2024 Apr; 39(2):118-125. PubMed ID: 38135836
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
    Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
    Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.
    Lan HR; Chen M; Yao SY; Chen JX; Jin KT
    Front Immunol; 2023; 14():1266450. PubMed ID: 38111570
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. First-line CDK4/6 inhibitor-based combinations for HR+/her2- advanced breast cancer: A Bayesian network meta-analysis.
    Guo X; Zhou Y; Zhang K; Lu W; Zhong X; Wu S; Shen L; Chen H; Chen Y
    J Evid Based Med; 2024 Mar; 17(1):106-118. PubMed ID: 38102891
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 29.